SkinBioTherapeutics PLC Total Liabilities

Latest as of June 2025: GBX2.71 Million GBX ≈ $329.31 USD

SkinBioTherapeutics PLC total liabilities. Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) has total liabilities worth GBX2.71 Million GBX (≈ $329.31 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See SBTX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Total Liabilities of SkinBioTherapeutics PLC (2016–2025)

Total liabilities of SkinBioTherapeutics PLC from 2016 to 2025. This chart illustrates how SkinBioTherapeutics PLC's total liabilities have evolved over time, based on quarterly financial data.

SkinBioTherapeutics PLC Competitors by Total Liabilities

The table below lists competitors of SkinBioTherapeutics PLC ranked by their total liabilities.

Company	Country	Total Liabilities
LIFT GLOBAL VENT. LS-01 F:7XO	Germany	€214.30K
Recon Technology Ltd NASDAQ:RCON	USA	$91.93 Million
GETT Gold Inc V:GETT	Canada	CA$18.53 Million
Manx Financial Group Plc LSE:MFX	UK	GBX517.76 Million
International Zeolite Corp V:IZ	Canada	CA$2.88 Million
XP Factory PLC LSE:XPF	UK	GBX61.15 Million
AA Mission Acquisition Corp. NYSE:AAM	USA	$10.16 Million
Subsea 7 SA LSE:0OGK	UK	Nkr2.37 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down SkinBioTherapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SBTX total asset value.

Liquidity & Leverage Metrics

SkinBioTherapeutics PLC Total Liabilities Ratios Explained

SkinBioTherapeutics PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	4.84	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.29	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.22	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SkinBioTherapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SkinBioTherapeutics PLC (2016–2025)

The table below shows the annual total liabilities of SkinBioTherapeutics PLC from 2016 to 2025.

Year	Total Liabilities	Change
2025-06-30	GBX2.71 Million ≈ $329.31	+20.55%
2024-06-30	GBX2.25 Million ≈ $273.17	+274.61%
2023-06-30	GBX599.34K ≈ $72.92	-1.68%
2022-06-30	GBX609.61K ≈ $74.17	+17.31%
2021-06-30	GBX519.67K ≈ $63.23	+70.48%
2020-06-30	GBX304.83K ≈ $37.09	+151.23%
2019-06-30	GBX121.33K ≈ $14.76	-42.03%
2018-06-30	GBX209.29K ≈ $25.46	+76.38%
2017-06-30	GBX118.66K ≈ $14.44	+252.72%
2016-06-30	GBX33.64K ≈ $4.09	--

About SkinBioTherapeutics PLC

LSE:SBTX UK Biotechnology

Market Cap

$307.45K

GBX2.53 Billion GBX

Market Cap Rank

#31243 Global

#977 in UK

Share Price

GBX9.75

Change (1 day)

+0.00%

52-Week Range

GBX5.20 - GBX21.50

All Time High

GBX75.50